2m 2m 2m 2m 2m 2m 2m
MEDICUS PHARMA (MDCX)
NASDAQ
$0.35-$0.01 (-2.96%)
Price as of Jun 03, 2026 7:59 PM EDT- $21.5MMarket Cap
- -86.76%1-Year Change
- Drug Manufacturers - GeneralIndustry
MEDICUS PHARMA (MDCX)
$0.35-$0.01 (-2.96%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | -197,382 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | -197,382 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -16.4M +365.98% | -3.5M N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 34.4M +207.30% | 11.2M N/A | |
Operating Profit | -34.4M +207.30% | -11.2M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -197,382 N/A | N/A N/A | |
Interest Income and Expense and Net | -197,382 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -1.1M -4,374.24% | 25,386 N/A | |
Income before Taxes | -47.3M +322.88% | -11.2M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -47.3M +323.84% | -11.2M N/A | |
Net Income from Continuing Operations Applicable to Common | -47.3M +323.84% | -11.2M N/A | |
Basic EPS and Net Income | -2.74 +136.21% | -1.16 N/A | |
Diluted EPS and Net Income | -2.74 +136.21% | -1.16 N/A | |
Basic Weighted Average Shares | 17.3M +79.68% | 9.6M N/A | |
Diluted Weighted Average Shares | 17.3M +79.68% | 9.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 8.7M +109.04% | 4.2M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 8.7M +109.04% | 4.2M N/A | |
Total Current Assets | 9.9M +83.90% | 5.4M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | |
Total Assets | 10.1M +78.18% | 5.6M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.2M N/A | N/A N/A | |
Total Current Liabilities | 9.9M +330.92% | 2.3M N/A | |
Total Long-Term Debt | 25,865 N/A | N/A N/A | |
Total Long-Term Liabilities | 60,139 -70.80% | 205,945 N/A | |
Total Liabilities | 10.0M +299.02% | 2.5M N/A | |
Retained Earnings | -64.3M +122.63% | -28.9M N/A | |
Total Stockholders Equity | -67,554 -102.16% | 3.1M N/A | |
Total Shares Outstanding | 25.2M +113.06% | 11.8M N/A | |
Cash Flow | |||
Cash from Operating Activities | -22.8M +122.27% | -10.2M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -4.6M N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 31.9M +151.65% | 12.7M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | 17,407.52% N/A | N/A N/A | |
Return on Assets | -602.00% N/A | N/A N/A | |
Return on Equity | -3,083.09% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 1.00 N/A | N/A N/A | |
Cash Ratio | 0.88 N/A | N/A N/A | |
Debt-to-Equity Ratio | -78.03 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.52 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow